HHS Scraps 340B Drug Pricing Program rebate model

The department of Health and Human Services (HHS) has abandoned its plan to implement a new rebate⁤ model for the 340B Drug Pricing Program, following legal challenges and concerns from hospitals and healthcare providers. The decision, formalized in a court filing on February 6, 2026, brings relief to hospitals that ⁤feared increased⁢ administrative burdens and financial strain.

Background of the 340B Program

The 340B program, established in 1992, allows⁢ eligible healthcare organizations – primarily hospitals‍ serving low-income ​and uninsured patients – to ⁢purchase outpatient drugs at considerably reduced ⁢prices. The program’s intent is to enable these providers to stretch scarce resources and provide affordable care ‍to vulnerable populations.⁣ Health Resources & Services Administration (HRSA) provides oversight of ⁢the 340B program.

The Proposed Rebate model and its ‌Challenges

In recent years,HHS proposed a rule to shift‌ the 340B discount from a front-end price reduction to a rebate ⁣system. Under this model, providers would have initially paid the ⁢full drug price and then received a rebate after purchase. This change was intended to increase transparency and ‍address concerns about duplicate discounts. However, ‍it quickly faced opposition.

Critics argued that the rebate model‍ would create critically‍ important administrative complexities, particularly for smaller, safety-net‍ hospitals. Providers like Vivent Health, a⁤ nationwide HIV care provider, expressed concerns about cash flow problems, especially with high-cost medications. For example, Biktarvy, a ‌common HIV ⁣treatment, costs approximately $4,200 per month, and the rebate model could have required clinics‍ to initially cover the full cost. Vivent Health

Legal Battles and ‌Opposition

The proposed ⁢rule triggered multiple lawsuits, most notably‍ one filed in December 2025 by the American Hospital Association (AHA) and ⁣a coalition of hospital groups.⁢ AHA lawsuit The AHA argued that the model was unlawful and would undermine the​ program’s ability to provide affordable ⁤care. Courts initially blocked the implementation of ‍the ⁢rule due to procedural and legal issues.

Reaction to the Withdrawal

The decision to ‍scrap the rebate model ​has been met ⁣with widespread approval from hospital associations and healthcare providers.

“A rebate program that undermines safety-net hospitals’ ability to offer more comprehensive care would only harm the‍ nation’s most vulnerable communities,”⁢ said Rick Pollack, CEO of the AHA, in a ⁢statement.

Tom Kraus,vice president of government relations at⁣ the ​American Society of Health-System Pharmacists (ASHP),called​ the model “unworkable and ⁢a threat to ⁢program integrity,” adding ⁢that rebates improperly shift costs to providers,